Clinicians should be aware of unusual manifestations of amiodarone pulmonary toxicity, including unilateral alveolar disease, pleural effusion, and potential responsiveness to corticosteroids even if amiodarone is continued.
Atypical amiodarone pulmonary toxicity features warrant inclusion in differentials; case reports leave open optimal management strategies.
Amiodarone is very useful treatment for refractory arrhythmias. However, it has a wide profile of adverse effects involving a number of organ systems. Pulmonary toxicity is the most serious of these side effects and often limits its clinical use. Three patients with unusual forms of amiodarone pulmonary toxicity are described. One had extensive unilateral alveolar disease, another pleural effusion, and in a third the pulmonary infiltrate improved with oral corticosteroids despite continuation of amiodarone therapy. Extensive unilateral alveolar disease and resolution of the pulmonary toxicity with corticosteroids despite continuing with amiodarone have not been previously reported. Pleural effusion has been noted only rarely. With the increasing use of amiodarone, pulmonary toxicity is likely to occur more frequently and it is important to be aware of its less common manifestations.
No takes yet. Share an insight, caveat, or question.
McNeil et al. (1992) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: